A federal jury in California has ruled that Apple must pay medical-technology company Masimo $634 million in damages, concluding that the tech giant infringed one of Masimo’s patents related to non-invasive blood-oxygen monitoring. The verdict represents one of the most significant legal setbacks Apple has faced in the growing and highly competitive health-wearables market.
The ruling caps a years-long dispute between the two companies, one that has intertwined issues of intellectual-property rights, hiring practices, import bans, and the rapidly increasing overlap between consumer electronics and clinical medical technology. While Apple immediately vowed to appeal, the decision adds a new layer of uncertainty to the future of Apple’s health-monitoring products and comes at a time when the company faces heightened regulatory and legal scrutiny globally.
Background of the Dispute
Masimo, a long-established company known for its hospital-grade pulse-oximetry technology, first accused Apple several years ago of misappropriating its technology and trade secrets. According to Masimo, Apple intentionally incorporated patented blood-oxygen monitoring methods into its smartwatch lineup without a license. The company also alleged that Apple recruited key Masimo employees during the development of the Apple Watch’s health-sensor features, giving Apple direct access to proprietary know-how and designs.
Apple has firmly denied wrongdoing from the outset. The company has insisted that its engineers developed the Apple Watch’s blood-oxygen feature independently and that any overlap with Masimo’s patents is either superficial, incidental, or covered by patents that expired years ago. Apple has also criticized what it describes as Masimo’s attempt to hinder competition by resorting to litigation rather than innovation.
Despite Apple’s arguments, the jury concluded that the company had violated Masimo’s patent rights. In particular, the panel focused on a patent describing methods for using light-based sensors and algorithms to measure oxygen saturation levels. The jurors ultimately agreed with Masimo that Apple’s implementation of blood-oxygen monitoring in certain Apple Watch models constituted infringement.
The $634 Million Verdict
The damages award of $634 million is substantial even by the standards of high-profile technology cases. Although Apple earns far more than that from its wearable product line, the verdict sends a strong signal regarding how seriously courts are taking intellectual-property claims in emerging consumer-health technologies. For Masimo, the judgment marks a major legal victory after years of costly litigation and a chance to reinforce its position as a pioneer in medical-grade sensor technology.
The jury’s figure covers both compensatory damages and additional penalties based on the perceived economic harm Masimo incurred from Apple’s use of its patented technology. The court will still need to address any additional motions or requests for enhanced damages, and Apple is expected to immediately challenge the verdict through post-trial filings.
Apple’s Response and Plans for Appeal
Shortly after the decision was announced, Apple said it “strongly disagrees” with the jury’s conclusion and intends to appeal. The company reiterated that the patent at the center of the case is rooted in decades-old designs and argued that Masimo has been pursuing Apple with a barrage of overlapping lawsuits in an effort to slow its progress in the health-wearables market.
Apple’s appeal is likely to focus on challenging the validity of the patent, arguing non-infringement, and raising questions about how the jury evaluated complex technical evidence. The appeals process could take months or even years, and Apple may seek to reduce or overturn the damages award during that time.
Regulatory and Market Implications
The verdict arrives at a time when Apple’s wearable products—especially the Apple Watch—have become increasingly dependent on health-monitoring features to differentiate themselves from competitors. The blood-oxygen sensor, along with heart-rate tracking and ECG capabilities, is a cornerstone of Apple’s marketing of its watches as tools for personal wellness and early detection of health issues.
But alongside this success has come heightened legal friction. Masimo has also pursued remedies through the U.S. International Trade Commission (ITC), which previously issued an import ban on certain Apple Watch models featuring blood-oxygen sensors. While Apple managed to delay or work around some of those restrictions by making changes to the product’s software and measurement methods, the latest verdict may strengthen Masimo’s leverage in ongoing regulatory and legal proceedings.
Industry analysts note that the verdict could also influence how other technology companies approach health-monitoring features. As consumer devices become more sophisticated and increasingly resemble medical equipment, companies face higher risks of infringing existing patents traditionally used in clinical settings. The Apple-Masimo dispute highlights the tension between rapid consumer-tech innovation and long-standing medical-technology patents.
What Comes Next
The case is far from over. Apple’s appeal is expected to be wide-ranging, and the company will continue to argue that its technology is fundamentally different from Masimo’s. Meanwhile, Masimo could seek additional court orders to limit the sale or import of devices Apple has already shipped or plans to release in the near future.
The verdict could also push the two companies toward a potential settlement or licensing agreement, though both sides have so far shown little public willingness to compromise.
For now, the $634 million judgment stands as one of the largest patent-infringement awards in the consumer-technology sector. The outcome underscores the escalating legal battles around health-sensor technology and signals that the future of wearable innovation will likely depend as much on courtrooms as on engineering breakthroughs.
